ProsTIC at Peter Mac is a world-leader in theranostics.

Meet the ProsTIC leadership team, scientific advisory team, CEO steering committee and staff.

This animation explains PSMA theranostics, a treatment that is increasingly being used for people with advanced prostate cancer and the focus of the world-leading research at ProsTIC at Peter Mac.

Clinical trials enable us to answer questions about what is the role of this new technology in improving patient care.

Radiolabelled prostate specific membrane antigen (PSMA) can be used for PET imaging and also treatment of patients with prostate cancer.

ProsTIC's world leading research in the news.

Centres of Excellence do not evolve on their own. They require the best team, processes and purpose to realise a goal.